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Abstract  
Human GLUT12 was isolated from the breast cancer cell line MCF-7 by its homology with GLUT4. 
Glucose has been described as its main substrate, but it also can transport other sugars. In humans, 
GLUT12 protein is expressed mainly in insulin sensitive tissues. Functional analysis has showed that 
GLUT12 transports sugars down its concentration gradient, but it can also work as a proton-coupled 
symporter. Studies from our laboratory, performed in Xenopus laevis oocytes expressing GLUT12, 
show that glucose uptake increases in the presence of Na+ and induces inward current. These findings 
suggest a transport mechanism never described for other GLUTs, which would indicate a distinct 
functional role for GLUT12. In relation with its physiological and pathophysiological function, 
GLUT12 has been mainly studied due to its role as a secondary insulin-sensitive glucose transporter 
and its possible implication in impaired insulin signalling pathologies. Its expression in some tumour 
tissues has been described and recently, it has been proposed as one of the key proteins in the glucose 
supply to malignant cells. Overall, even though a lot of information about GLUT12 has been released 
during the last years, its functional characteristics, physiological role or implication in the development 
of some diseases is still unclear. Therefore, this review of the literature can help to address further 
investigations needed to elucidate these issues that, in our view, are of great interest mainly due to the 
direct GLUT12 relation with cancer and probably with diabetes development. 
 
Introduction 
Glucose, one of the most abundant molecules in nature, is used by most of the mammalian cells as their 
main energy source. Obtained from the diet, glucose is absorbed in the small intestine, incorporated 
into the circulating blood and stored as glycogen, mainly in the liver and muscle. Due to its hydrophilic 
nature, glucose cannot cross the plasma membrane by simple diffusion; instead, glucose enters the cell 
by specific membrane transporters. There are two families of glucose transporters, distinguished by 
their functional and structural properties: the Na+/ glucose cotransporter family SGLT/SLC5A [47] and 
the facilitative glucose transporter family GLUT/SLC2A [11, 22]. 
GLUT protein family members transport monosaccharides across the plasma membrane without 
energetic requirement, using the favourable concentration gradient of the hexose generated in some 
physiological situations. GLUTs share a common structural feature of 12 transmembrane domains, 
with both amino and carboxy terminal domains located on the cytosolic side, and a N-linked 
oligosaccharide site present either on the first or on the fifth extracellular loop [37]. At present, 14 
different members of this family, divided in three classes according to its sequence homology, have 
been identified [11]. Class I is constituted by the well characterized GLUT1, GLUT2, GLUT3, GLUT4 
and GLUT14 (gene duplication of GLUT3); Class II comprises the fructose transporter GLUT5, and 
GLUT7, GLUT9 and GLUT11; and class III includes GLUT6, GLUT8, GLUT10, GLUT12 and 
GLUT13 (HMIT) [12]. In relation to this classification, a recent phylogenetic analyses proposes that 
the proteins belonging to Class III could be separated into three different groups and, therefore, suggest 
five structurally and/or functionally distinct GLUT classes (Figure I) [43].  
Location, expression and regulation of the GLUT transporters are specific for each tissue and cellular 
type and is related to the cell metabolic needs. In many cases, the up or down-regulation of the GLUT 
proteins is directly linked to the development of diseases (Table I). GLUT1, 2, 3, 4 and 5 were the first 
members of the GLUT family cloned and their physiological function has been well characterized. 
GLUT9 seems to be an urate transporter, newly described as electrogenic [44], while GLUT13 (HMIT) 
is a H+-dependent myoinositol cotransporter [36]. However, the physiological significance of the rest 
of GLUT transporters of class II and III still needs to be elucidated. Therefore, it is important to 
continue investigating the location and cellular function of recently discovered GLUT transporters, not 
only to determine their function in the organism, but also to understand their contribution in some 
diseases, thus giving the possibility of using them as therapeutic targets.  
Consequently, the objective of the present review is to summarize the current information about 
GLUT12, including some new data from our laboratory, and give some proposals for future studies that 
could help to better understand its relevance in the organism both in health and disease.  
GLUT12 
Structure and Tissue Distribution 
Human GLUT12 cDNA was isolated from the breast cancer cell line MCF-7 by its homology with 
GLUT4 [30]. GLUT12 gene has five exons and encodes a 617 amino acid protein with a predicted 
molecular mass of 50 kDa. Its structure comprises 12 transmembrane domains, with the conserved 
features of the glucose transporters family for the substrate-binding site and catalytic activity [43]. As 
the other members of Class III, its membrane topology predicts an exofacial loop between helices 9 
and 10 with a N-linked glycosilation site, and the absence of the exofacial loop between the first two 
helices described for Class I [11] (Figure 2).  Interestingly, in helix 7 GLUT12 does not present the 
QLS motif, which is highly conserved in GLUT1, GLUT3 and GLUT4; however it contains an 
isoleucine in the third position of the NXI/V motif like GLUT2, GLUT5 and GLUT7 [22]. The absence 
of this QLS motif in GLUT2 and GLUT5 and the presence of a key hydrophobic residue in position 
314, such as isoleucine in GLUT2, GLUT5 and GLUT7, have been described as essential for fructose 
transport [1, 21]. Finally, it is remarkable that GLUT12, as the rest of class III transporters and 
GLUT4, possesses the internalization di-leucine motifs at the N- and C-terminal ends of the protein, 
that retain these transporters into intracellular compartments in the absence of stimulus [30] (Figure 2). 
In fact, in the absence of insulin, GLUT12 was localized in the perinuclear region of MCF-7 cells [30]. 
GLUT12 cDNA has also been cloned from mouse and cow, presenting respectively 83 and 87 % 
homology with the human isoform [24, 49], and expression of GLUT12 has been reported in rat [18], 
horse [38] and dog [41]. 
In relation to its tissue distribution, in human GLUT12 protein is expressed in skeletal muscle, adipose 
tissue, small intestine [30] and placenta [10]. Its mRNA is abundant in skeletal muscle, heart and 
prostate, and it is present at low levels in brain and kidney [30]. In rat, expression of GLUT12 protein 
has been described during foetal development in skeletal muscle, brown adipose tissue, heart, foetal 
chondrocytes, lung, kidney [18], mammary gland during pregnancy [19] and kidney distal tubes and 
collecting ducts [15]. In cow, its mRNA expression is abundant in spleen and skeletal muscle, less 
expressed in kidney, testis and mammary gland, and even lower expressed in liver, lung and intestine 
[24]. GLUT12 protein expression has also been found in Chinese hamster ovary cells [7], horse 
skeletal muscle [38] and dog heart muscle [41]. 
Functional characteristics 
Analysis of glucose transport in GLUT12 cRNA injected Xenopus laevis oocytes, showed that 
radiolabeled 2-deoxy-glucose (2-DOG) uptake was 6-fold higher than in water-injected oocytes. 
Uptake of 2-DOG was also measured in the presence of different sugars, showing the following 
substrate selectivity: D-Glucose > 2-DOG > D-Galactose > D- Fructose > L-Glucose. Transport of 2-
DOG into the oocytes was inhibited by cytochalasine B, a GLUTs specific inhibitor [28].  Further 
analysis of the functional glucose transport in canine kidney epithelial cell line (MCDK), showed that 
GLUT12 can work as a proton-coupled symporter, transporting glucose against its concentration 
gradient. This transport mechanism was also inhibited by cytochalasine B and was pH dependent [43]. 
Preliminary studies from our laboratory, using Xenopus laevis oocytes as expression system, have 
shown that glucose transport by GLUT12 increases in the presence of Na+ (Figure 3). Furthermore, 
studies using electrophysiological techniques showed that GLUT12 mediated glucose transport induce 
electrical currents (Figure 4), confirming that the GLUT12 transport mechanism is coupled to ions 
movement. 
Physiological role 
GLUT12 has been mainly studied due to its role as a secondary insulin-sensitive glucose transporter in 
insulin dependent tissues. This physiological function was demonstrated in normal human skeletal 
muscle, where it was described that GLUT12 is translocated to the plasma membrane together with 
GLUT4 in response to insulin [32]. This fact was recently confirmed in a GLUT12 over-expressing 
mice, where the whole body insulin sensitivity and the glucose clearance rate in insulin sensitive 
tissues was higher than in control mice [26]. In normal human skeletal muscle, it has been described 
that GLUT12, GLUT4 and GLUT5 account for 98 % of the total GLUT mRNA, with an expression 
ratio for GLUT4: GLUT12 of 12:1, and being GLUT12 predominantly co-expressed with GLUT4 in 
type I fibers [33]. In another study, it has been shown a protein expression ratio for GLUT4: GLU12 of 
8:1, representing for GLUT12 around 12 % of the potentially insulin translocable GLUT. Moreover, 
activation of PI3-K was involved in GLUT12 translocation, as has been described for GLUT4 [32].  
Regarding adipose tissue, GLUT12 mRNA is expressed in all the major adipose tissue depots in rat, 
but not in the 3T3-L1 murine adipocytes cell line [45]. In humans, GLUT12 mRNA has been found in 
omental and subcutaneous depots and also in the human SGBS adipocyte cell line [45]. Further studies 
from the same group have demonstrated in human adipocyte primary culture, an increase of 2-DOG 
uptake due to hypoxia, without modification of GLUT12 mRNA levels [46].  
In addition to its role as a secondary insulin sensitive transporter, GLUT12 has been also studied in 
other physiological conditions as foetal development and mammary gland during pregnancy and 
lactation.  
GLUT12 protein expression has been largely investigated during rat foetal development, when glucose 
delivery is particularly important because cells are rapidly dividing and differentiating. The studies 
showed that during gestational period, from day 15 to 21, GLUT12 is expressed in insulin sensitive 
tissues as heart, skeletal muscle and brown adipose tissue. During similar gestational period, GLUT12 
was also detected in chondrocytes, kidney distal tubules and collecting ducts, and in lung bronchioles. 
According to these data, authors propose that GLUT12´s physiological role during rat foetal 
development could be related to the uptake of different hexoses, other than glucose, and the glucose 
delivery to insulin sensitive tissue before GLUT4 appearance [18]. In extracts of human placenta from 
the first trimester and at term, a spatio-temporal difference in GLUT12 protein expression was 
described. This different expression pattern matches with the location of placenta insulin receptors 
during foetal development, and authors propose that GLUT12 could be responsible of insulin regulated 
glucose uptake in that tissue [10]. In human term placenta, GLUT12 mRNA and protein have been 
detected in omnion and choriodecidua cells [9].  
Glucose is very important for the mammary gland function during lactation, as glucose is used as an 
energy source and milk precursor. Presence of GLUT12 protein has been described in the cytoplasm, 
likely associated with vesicles and/or the Golgi apparatus, of rat mammary epithelial cells during the 
final period of pregnancy and postpartum. In contrast, during lactation, GLUT12 is present at the apical 
membrane of those cells. As it is the only GLUT isoform described in the apical membrane of 
mammary glands, authors suggest that GLUT12 is the responsible for glucose transport into the milk 
[19]. Supporting these findings, GLUT12 was also identified in the cytoplasm of cow mammary 
epithelial cells and in a bovine mammary epithelial cell line (MAC-T). It is interesting to mention that 
cow GLUT12 does not have a dileucine motif at the C-terminal region, suggesting different function 
and/or regulation of GLUT12 in this animal [24]. 
Implication in Cancer and Other Diseases 
Malignant cells are characterized by uncontrolled cellular division and accelerated metabolism that 
implies high glucose requirement and, therefore, increased glucose uptake. To satisfy this glucose 
need, GLUTs are overexpressed in malignant cells [17]. Therefore, as glucose transport across the 
plasma membrane is the first rate-limiting step for glucose metabolism, and GLUTs overexpression is 
related to accelerated metabolism, GLUTs are widely studied in cancer for diagnosis and even 
treatment purposes. In this regard, GLUT12 protein expression has been described in the MCF7 
malignant breast epithelial cell line [30], in human breast tumours [29] and in human prostate 
carcinoma cell lines and tissue samples [5]. On the other hand, GLUT12 protein expression is 
increased by stimulators of breast cancer cell growth such as estradiol and epidermal growth factor, 
which may indicate that GLUT12 contributes to increase glucose uptake in breast cancer [17]. 
Differential expression of GLUTs mRNA in normal and tumour kidney tissue suggests that GLUT4 
and GLUT12 could be possible candidates for the increased glucose uptake in chromophobe renal cell 
carcinoma [35].  
More interestingly, recent experiments performed to develop strategies for anticancer therapy have 
shown that GLUT12 together with GLUT1, are the main glucose transporters involved in the glycolytic 
metabolism characteristic of human cancers, known as the Warburg effect [40]. In those studies, 
authors showed that p53 transcription factor, a tumour development suppressor, specifically binds, 
among other genes, to the GLUT12 and GLUT1 promoters and repress their expression. In addition, 
the pharmacological activation of p53 inhibits the glycolytic metabolism, even under hypoxic 
conditions, in different cancer cell lines [48]. 
As an insulin sensitive transporter, GLUT12 expression has been largely studied in insulin sensitive 
tissues in different physiological and pathophysiological conditions and mainly in those with impaired 
insulin signalling, as in type II diabetes. In human muscle biopsies, GLUT12 mRNA levels decreased 
(40 %) in endurance-trained compared to sedentary individuals, whereas GLUT4 mRNA increases (78 
%) [31]. In contrast, other studies indicated that cycle training increases protein expression of GLUT4 
(66%) and GLUT12 (104%), compared to sedentary subjects, together with the activation of the mTOR 
muscle hypertrophy pathway [34]. In an equine model of insulin resistance (IR) an increase of GLUT4 
basal cell-surface expression has been found, but not for GLUT12, without modification of GLUT4 
and GLUT12 total protein levels [38]. In adipose tissue from the same IR equine model, cell-surface 
GLUT4 content was lower in visceral and subcutaneous depots compared to insulin sensitive animals, 
while total GLUT4 content was only reduced in omental tissue. However, neither total nor cell-surface 
GLUT12 protein content was affected in any adipose depot in the IR animals [39]. In a Ren-2 rat 
model of diabetic nephropathy, GLUT12 overexpression was described in distal tubules and collecting 
ducts compared to control animals, suggesting that GLUT12 could be involved in the regulation of 
glucose reabsorption in distal renal tubules in response to elevated glucose levels [15]. Further analysis 
of GLUT12 cellular location and targeting in the MDCK cell line demonstrated apical targeting of 
GLUT12 from the perinuclear location, in response to elevated glucose concentration, in which mTOR 
signalling pathway was involved. Activity of mTOR signalling pathway has been associated with 
diabetic kidney nephropathy [42]. Finally, in a canine model of chronic heart failure, increase of 
GLUT4 and GLUT12 protein and mRNA expression was described in comparison to control heart 
samples [41].   
Summary and Future directions 
GLUT12 was one of the last glucose transporters to be cloned [30]. During the past years, research has 
focused on the study of GLUT12 role as a secondary insulin sensitive transporter [26, 32] and its role 
on impaired insulin signalling pathologies [15, 38, 39]. Its expression in some tumour tissues has been 
described [5, 29, 35] and recently it has been proposed as one of the key proteins in the glucose supply 
to malignant cells [48] (Figure 5). 
Taking into account the information presented in this review and our preliminary experimental data, we 
would like to propose some questions in order to address future investigations about GLUT12 
physiology. 
1) Functional features described for GLUT12 are very different from those of GLUT4. GLUT12 can 
transport various hexoses other than glucose [28], it is able to transport glucose against its 
concentration gradient through a proton-coupled symport mechanism [43] and, according to our 
preliminary data, presents electrogenic properties and its transport mechanism is modified in the 
presence of extracellular Na+. Therefore, instead of being an evolutionary GLUT4 ancestor, maintained 
as a backup [32], could GLUT12 complement GLUT4 activity? 
2) Changes in GLUT4 and GLUT12 expression pattern have been described both during physical 
training [31] and in the development of insulin resistance [38]. If there is a loss of function of GLUT4, 
as described in human adipose tissue in insulin resistance [37], could this loss be counter-balanced with 
an increase in GLUT12 expression? Would the response to insulin be the same?  
3) GLUT12, together with GLUT1, has been described as the main glucose transporters in the 
glycolytic metabolism of malignant cells [48]. In agreement with this, in the tumours where the 
expression of GLUT12 has been reported (prostate, breast and kidney) [5, 29, 35], can be the 
expression of GLUT12 considered as tissue specific or is a consequence of a predominant glycolytic 
metabolism? And, if a glycolytic metabolism is a common feature of most tumours, can we expect 
GLUT12 expression in all of them?  
4) GLUT12 expression has been reported in small intestine, but its location is still unknown. Assuming 
that in basal conditions it would be located in cytoplasm vesicles, could it be possible that at high 
luminal glucose concentration, as described for MCDK cells [42], GLUT12 would be translocated to 
the apical plasma membrane during intestinal glucose absorption? 
5) Recently, phylogenetic studies have reported that GLUT10 and GLUT12 may constitute a new 
GLUT family class [43], and as they are evolutionary close to the proton-myoinositol transporter 
HMIT (GLUT13), could it be possible that GLUT10 share with HMIT and GLUT12 some of their 
particular functional features?   
In conclusion, even though a lot of information about GLUT12 has been released during the last years, 
still little is known about its functional characteristics, and its physiological role is not clear yet. 
Therefore, further studies are needed to elucidate these issues in order to establish a solid body of 
knowledge of GLUT12. In our view, this is of great interest due to GLUT12 direct relation to the 
glycolytic metabolism of malignant cells, its role as insulin sensitive transporter and maybe, as a 
possible therapeutic target to fight against diseases of high prevalence in our society as cancer and 
diabetes. 
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 Figure Legends 
Figure 1. Dendogram of multiple alignments of all members of the facilitative glucose 
transporters family GLUT/SLC2A. Alignment was performed using the CLUSTAL W online tool 
from the European Bioinformatics Institute (EBI). The division of GLUT/SLC2A family proposed in 
[43] is indicated with dashed lines boxes, while classic division is indicated with solid bold lines.         
Figure 2. Schematic model of GLUT12 protein with its predicted 12 trans-membrane domains. 
N-glycosylation site is located between trans-membrane domains 9 and 10 (N). Characteristic di-
leucine motifs (LL) are located at the amino and carboxy terminal ends and NXI motive in trans-
membrane domain 7. 
Figure 3. Effect of Na+ on 5 mM glucose uptake in Xenopus laevis oocytes expressing GLUT12. 
Stage VI oocytes from X. laevis were obtained and microinjected with 50 nl of GLUT12 mRNA as 
previously described [14]. After 3-5 days, 5 mM glucose uptake was determined after 15 min 
incubation, using the radiotracer method [16] in the presence of Na+ buffer (NaCl 100 mM, KCl 2 mM, 
MgCl2 1 mM, CaCl2 1mM, Hepes 10 mM, pH 7.5) or Na+-free buffer (ChCl 100 mM, KCl 2 mM, 
MgCl2 1 mM, CaCl2 Hepes 10 mM, pH 7.5). Values are the mean of 8-10 oocytes and error bars 
indicate standard error. In the presence of Na+ uptake increased ~ 45 %. Similar results were obtained 
with oocytes from at least three different animal donors. NI, non-injected oocytes.  
Figure 4. Current induced by glucose in Xenopus laevis oocytes expressing GLUT12. Currents 
associated to the transport of glucose mediated by GLUT12 were recorded using the two-electrode 
voltage-clamp technique [3]. A GLUT12 expressing oocyte was perfused with Na+ buffer (solid box) 
and a stable base-line current was recorded. The perfusion of 100 mM glucose (
↓
) induced a current of 
65 nA.  After the perfusion of glucose, oocyte was washed out with Na+-free buffer (white box) and the 
base-line current and glucose induced current disappeared. B For control, the same experiment was 
performed in a non-injected oocyte from the same batch and no response to glucose was obtained.  
Similar results were obtained with oocytes from more than 10 different animal donors.  
 
 
Figure 5. Scheme of the most relevant features described about GLUT12 and some of the 
questions still without response.  Glut12 is expressed in insulin sensitive tissues (muscle and adipose 
tissue) where its function is related with glucose transport in response to insulin stimulation. It is also 
expressed in small intestine but its role in this tissue is still unknown. In relation to its functional 
characteristics, GLUT12 could transport glucose down its concentration gradient (equilibrative 
transport) or against its concentration gradient (concentrative transport) in cotransport with H+ or, 
according to our preliminary data, Na+. GLUT12 transports different sugars as glucose, fructose and 
galactose. GLUT12 expression has been described in prostate and breast tumours and its role as one of 
the main glucose suppliers to glycolytic metabolism has been proposed.  As secondary insulin sensitive 
transporter, GLUT12 possible relation with diabetes has been studied, but its role is still unclear. 
 
